Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Nav

General Info

Geography

Canada (CAN)

United States of America (USA)

Puerto Rico, United States Virgin Islands

Time period covered

01/1994 - 12/2002

Data type

Scientific literature

Keywords

Ischemic heart disease, Peripheral vascular diseases, Stroke, Blood pressure

Citation

Authors

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial

Journal

JAMA

Volume

288

Issue

Pages

2981-97

Publication year

2002

Suggested citation

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288(23): 2981-97.

GHDx Entry last modified on: May 30, 2020

Header sites

Search form

Main menu

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Nav